Feedback / Questions
micvotabart pelidotin (PYX-201) - Pyxis Oncology
https://www.manilatimes.net/2026/09/09/tmt-newswire/globenewswire/pyxis-oncology-announces-positive-updated-data-from-phase-1-monotherapy-study-of-micvotabart-pelidotin-micvo-in-second-line-and-beyond-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma-2l-rm-hnscc/2421394
Sep 9, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next